Better Health, Brighter FutureNews Release

Takeda Establishes Record Date for the Extraordinary General Meeting of Shareholders
Company Announces Record Date and Highlights Significant Progress To-DateOsaka, Japan - September 28, 2018 – Further to the announcement of the recommended acquisition ofShire plc (“Shire”) on May 8, 2018 (“the Acquisition”), Takeda Pharmaceutical Company Limited (TSE:4502) (“Takeda” or the “Company”) today announced that the Company has established the record date for
the Extraordinary General Meeting of Shareholders, to vote on the necessary matters relating to the proposedAcquisition as follows.
Record Date Regarding the Extraordinary General Meeting of Shareholders
Takeda has set October 19, 2018 as the record date. Shareholders recorded in the final shareholder registryon that date shall be entitled to exercise voting rights at the Extraordinary General Meeting of Shareholders.
Establishment of an October 19, 2018 record date gives the company the discretion to hold the Extraordinary
General Meeting of Shareholders within the three month period ending January 18, 2019. If the company
does not decide to hold the Extraordinary General Meeting of Shareholders on any date falling within thethree month period ending January 18, 2019, a new record date will be established and announced.
1. Record date:
2. Date of public notice:
3. Method of public notice:

October 19, 2018
October 1, 2018
The relevant information will be posted on the Takeda website by anelectronic public notice (Japanese only).

Significant Progress To-Date
Since the announcement of the recommended offer on May 8, 2018, Takeda has successfully completed
several significant milestones in the Acquisition process, including:••••Entering into a USD 7.5 billion term loan credit agreement with leading global financial institutions.
Confirming a post-closing focus on key therapeutic areas including gastroenterology, oncology,neuroscience and rare diseases as well as vaccines and plasma-derived therapies.
Developing a future operating model as part of planning efforts to facilitate the successful
integration of Takeda and Shire following completion of the Acquisition. Takeda is planning toimplement a lean post-closing organizational structure with clearly-defined accountabilities andownership. The future operating model is intended to further strengthen Takeda’s patient- andcustomer-centric organization.
Receipt of unconditional clearance from regulatory agencies in a number of key jurisdictions,
including the United States Federal Trade Commission, the Brazilian Administrative Council for1Economic Defense and the State Administration for Market Regulation in China, among otherregulatory authorities.
The Acquisition will create a global, values-based, R&D-driven biopharmaceutical leader headquartered inJapan. It will strengthen Takeda’s presence in the United States, an important and growing market, willreinforce our pipeline, and provide cash flow to continue to invest in our R&D engine while creating a morecompetitive, agile and highly profitable company.
The significantly strengthened cash flow generation which the Acquisition is expected to provide will
support the maintenance of Takeda’s well-established dividend policy and facilitate rapid de-leveraging to anet debt to EBITDA ratio of 2.0x or less within three to five years following closing of the Acquisition. To
help accelerate the de-leveraging process and ensure an optimal business mix, Takeda may consider selected
divestitures of non-core businesses.

About Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited (TSE: 4502) is a global, research anddevelopment-driven pharmaceutical company committed to bringing better health and a brighter
future to patients by translating science into life-changing medicines. Takeda focuses its R&D
efforts on oncology, gastroenterology and neuroscience therapeutic areas plus vaccines. Takeda
conducts R&D both internally and with partners to stay at the leading edge of innovation.
Innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence inemerging markets, are currently fueling the growth of Takeda. Approximately 30,000 Takeda
employees are committed to improving quality of life for patients, working with Takeda’s partners
in health care in more than 70 countries.
For more information, visit https://www.takeda.com/newsroom/
Media Contacts:
Takeda (Investor Relations)Takashi Okubo
takeda.ir.contact@takeda.com+81 3 3278 2306
Takeda (Media - outside Japan)
Elissa Johnsen
Elissa.Johnsen@takeda.com+1 312 285 3203
Takeda (Media - within Japan)
Kazumi Kobayashi
Kazumi.Kobayashi@takeda.com+81 3 3278 2095###2